CCS adapting to COVID-19 realities to support Canadians during and after the pandemic
Treatments for recurrent oral cancer
Recurrent oral cancer means that the cancer has come back after it has been treated. The following are treatment options for recurrent oral cancer. The treatment for recurrent cancer depends on where the cancer comes back and what treatments were used before. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.
Surgery may be used to treat recurrent oral cancer. It may be used to remove a tumour that recurs locally or regionally.
You may be offered radiation therapy for recurrent oral cancer if radiation therapy was not previously used to treat the cancer.
You may be offered chemotherapy for recurrent oral cancer. If you haven’t had radiation therapy before, you may have chemotherapy along with radiation therapy (called chemoradiation).
An immunotherapy drug may be given if the cancer comes back (recurs) or spreads and has stopped responding to chemotherapy with drugs such as cisplatin or carboplatin. The most common immunotherapy drug used to treat oral cancer is nivolumab (Opdivo).
If you can’t have or don’t want cancer treatment
You may want to consider a type of care to make you feel better without treating the cancer itself. This may be because the cancer treatments don’t work anymore, they’re not likely to improve your condition or they may cause side effects that are hard to cope with. There may also be other reasons why you can’t have or don’t want cancer treatment.
Talk to your healthcare team. They can help you choose care and treatment for advanced cancer.
Talk to your doctor about clinical trials open to people with oral cancer in Canada. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.
How can you stop cancer before it starts?
Discover how 16 factors affect your cancer risk and how you can take action with our interactive tool – It’s My Life! Presented in partnership with Desjardins.